Literature DB >> 19894033

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

Rebecca A Miksad1, Kuan-Chi Lai, Marion C Stein, Megan E Healy, Rafael Rojas, Katherine M Krajewski, Andrew X Zhu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19894033      PMCID： PMC3417813          DOI： 10.1007/s12029-009-9086-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  17 in total

1.  Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia.

Authors:  Bungo Saito; Tsuyoshi Nakamaki; Hidetoshi Nakashima; Takako Usui; Norimichi Hattori; Keiichiro Kawakami; Shigeru Tomoyasu
Journal:  Am J Hematol       Date:  2007-04       Impact factor: 10.047

2.  Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

Authors:  Rangaswamy Govindarajan; Josna Adusumilli; Donna L Baxter; Anthony El-Khoueiry; Sami I Harik
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

3.  Complete cerebral response with sunitinib for metastatic renal cell carcinoma.

Authors:  J Medioni; O Cojocarasu; J-L Belcaceres; P Halimi; S Oudard
Journal:  Ann Oncol       Date:  2007-07       Impact factor: 32.976

4.  Reversible posterior leukoencephalopathy syndrome induced by sunitinib.

Authors:  German Martín; Lorena Bellido; Juan Jesus Cruz
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

5.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

6.  VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.

Authors:  Z G Zhang; L Zhang; Q Jiang; R Zhang; K Davies; C Powers; N v Bruggen; M Chopp
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

7.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

Authors:  Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

8.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Authors:  Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
Journal:  Mol Cancer Ther       Date:  2003-05       Impact factor: 6.261

9.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

10.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Authors:  Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544
View more
  1 in total

1.  Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

Authors:  Andrew X Zhu; Dan G Duda; Marek Ancukiewicz; Emmanuelle di Tomaso; Jeffrey W Clark; Rebecca Miksad; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2010-09-15       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.